Colorectal Cancer
An Introduction to Colorectal Cancer
Colorectal cancer (CRC) is the third leading cause of cancer death worldwide. The mainstay of treatment for advanced disease is chemotherapy combined with angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors, but outcomes and toxicity are highly variable. Recent advances include combined small molecule/monoclonal antibody therapies for CRC with the V600E mutation in the BRAF gene for metastatic disease and immune checkpoint inhibition.
Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Dr Frank Sinicrope presented results from the ATOMIC trial at #ASCO25, showing that adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in stage III dMMR colon cancer. With no major safety concerns, the findings support chemo-immunotherapy as a new standard of care for this patient group.
At #ASCO25, Dr Frank Sinicrope discussed major colon cancer trial updates, including ctDNA’s prognostic power post-surgery, the limitations of chemotherapy escalation in high-risk patients, and survival gains with first-line encorafenib + cetuximab + mFOLFOX6 in BRAF-mutant mCRC. These findings may reshape risk stratification and frontline treatment strategies.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.
This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.
At a time when cancer research is experiencing uncertainty and setbacks in America, the Colorectal Cancer Alliance (Alliance) is strengthening its commitment to its Project Cure CRC initiative because tomorrow can’t wait. Project Cure CRC funds cutting-edge colorectal cancer (CRC) research and aims to improve patient outcomes through its dynamic patient navigation portal, BlueHQ.org.
Dr Satish Nadig describes Northwestern Medicine’s first use of the RAPID procedure to treat metastatic colorectal cancer with liver transplantation. He outlines the innovative surgical techniques, the promise of the CLEAR program, and the future potential of machine perfusion technology to extend transplant opportunities to more patients.
Q&A with Dr Benjamin Weinberg: Understanding rare GI cancers (small bowel, appendix and anal cancer)
Rare gastrointestinal (GI) cancers present unique challenges in diagnosis, treatment and research. Dr. Benjamin Weinberg discusses three of the rarest GI cancers: small bowel, appendix and anal cancer.
[embed]https://www.youtube.com/watch?v=Cd77dEeZfrc[/embed] As the leading nonprofit organization dedicated to ending the disease, the Colorectal Cancer Alliance (Alliance) continues to break boundaries in colorectal cancer care. Its Project Cure CRC research initiative ...
What’s new in GI oncology? With the 2025 ASCO Gastrointestinal Cancers Symposium still fresh in our minds, we hear from leading experts on the key abstracts and presentations from the conference in the fields of colorectal and pancreatic cancer. Circulating ...
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...
Project Cure CRC, the breakthrough research fund of the leading nonprofit Colorectal Cancer Alliance (Alliance), has announced five new awardees of funds to advance urgent science in the colorectal cancer space. To date, 10 research grants have been awarded for a ...
Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1Â Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2Â ...
Colorectal cancer is the third most common cancer worldwide and is the second leading cause of cancer-related deaths for men and women combined. The disease is on the rise in younger generations. It is the leading cause of cancer-related deaths in men under 50, and researchers predict it will become the leading cause in men and women ages 20-49 within the next decade. However, it remains less known and less funded than other cancers. For comparison, breast cancer, which has benefited greatly from major funding that contributed to significant research advancements, has a five-year survival rate of 30%, whereas the five-year survival rate for colorectal cancer is drastically lower at only 13%. To achieve better outcomes, the Colorectal Cancer Alliance (Alliance) is reinvigorating its mission to end colorectal cancer with the launch of Project Cure CRC.
The ESMO GI 2024 meeting, held this year in Munich, Germany, brought together researchers and clinicians from around the world to discuss recent developments in gastrointestinal malignancies.
Practice-changing data in the field of gastrointestinal cancer was presented at ASCO 2024. To understand these, as well as the other highlights from the meeting, we spoke with Assistant Professor of Medicine (Medical Oncology), Yale School of Medicine, Dr Michael Cecchini. In this interview, Dr Cecchini discusses the findings from the ESOPEC (NCT02509286), TRANSMET (NCT02597348), COLLISION (NCT03088150), ARC-9 (NCT04660812), ABBV-400 (NCT05029882) and other presentations, offering his valuable insights into the impact the results could have on clinical practice.
Outcomes for patients with metastatic colorectal cancer have steadily improve due to discovery of new drugs as well as increasing number patients undergoing local therapies.1Â Angiogenesis is of a paramount importance in this disease and since vascular endothelial growth factor (...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
